Publications by authors named "John A Kosteva"
Background: Immune checkpoint inhibitor (ICI) consolidation following concurrent chemoradiotherapy (CRT) substantially improved progression free survival (PFS) and overall survival (OS) in the PACIFIC trial becoming the standard of care in locally-advanced, unresectable NSCLC. KRAS mutation may influence response to ICI.
Methods: In this single-institution, retrospective analysis, we compared treatment outcomes for patients with unresectable KRAS mutated (KRAS-mt) and wild-type (KRAS-wt) NSCLC treated with CRT between October 2017 and December 2021.
Objectives: We sought to determine the proportion of patients with stage III non-small cell lung cancer (NSCLC) who initiate consolidation durvalumab or other immune checkpoint inhibitors (ICIs) after concurrent chemoradiotherapy (cCRT), as well as reasons for nonreceipt and prognostic implications.
Materials And Methods: We retrospectively identified consecutive patients with unresectable stage III NSCLC treated with definitive cCRT between October 2017 and December 2021 within a large US academic health system. Patients either received consolidation ICIs (ICI group) or did not (no-ICI group).
Objectives: Efficient use of nivolumab in non-small-cell lung cancer (NSCLC) has been limited by the lack of a definitive predictive biomarker. In patients with metastatic melanoma treated with ipilimumab, a pretreatment neutrophil-to-lymphocyte ratio (NLR)<5 has been associated with improved survival. This retrospective cohort study aimed to determine whether the pretreatment NLR was associated with outcomes in NSCLC patients treated with nivolumab.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluates the effectiveness of using cell-free circulating tumor DNA (ctDNA) next-generation sequencing (NGS) as a potential substitute for traditional tissue biopsies in identifying genetic alterations in advanced non-small cell lung cancer (NSCLC).
- Of the 112 plasma samples analyzed, ctDNA NGS detected mutations in 86 out of 102 patients, including significant driver and resistance mutations, which were not always identifiable through tissue samples.
- The findings suggest that ctDNA NGS can reliably identify actionable mutations, aiding in patient diagnosis and treatment management even when tissue samples are limited or unavailable.